32 articles for MA Siddiqui
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
27
Discovery of novel spiro 1,3,4-thiadiazolines as potent, orally bioavailable and brain penetrant KSP inhibitors.
Merck Research Laboratories
25
Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor.
Merck Research Laboratories
46
Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitors.
Merck Research Laboratories
46
Synthesis and SAR studies of imidazo-[1,2-a]-pyrazine Aurora kinase inhibitors with improved off-target kinase selectivity.
AMRI
18
Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y(1) receptor ligands.
National Institute of Diabetes
13
Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists.
National Institute of Diabetes
25
Discovery of imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
Merck Research Laboratories
41
Structure and activity relationships of tartrate-based TACE inhibitors.
Merck Research Laboratories
41
2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.
Merck Research Laboratories
32
Novel TNF-a converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases.
Merck Research Laboratories
57
Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors.
Merck Research Laboratories
6
Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors.
Merck Research Laboratories
36
Biaryl substituted hydantoin compounds as TACE inhibitors.
Merck Research Laboratories
1
An efficient preparation of the potent and selective pseudopeptide thrombin inhibitor, inogatran
TBA
24
Design, synthesis, and evaluation of benzhydrylpiperazine-based novel dual COX-2/5-LOX inhibitors with anti-inflammatory and anti-cancer activity.
India Institute of Technology (Banaras Hindu University)
20
Novel bicyclic lactam inhibitors of thrombin: highly potent and selective inhibitors.
Shire Biochem
11
Novel bicyclic lactam inhibitors of thrombin: potency and selectivity optimization through P1 residues.
Shire Biochem
11
Potent and selective bicyclic lactam inhibitors of thrombin. Part 4: transition state inhibitors.
Biochem Pharma
2
Structural basis of the thrombin selectivity of a ligand that contains the constrained arginine mimic (2S)-2-amino-(3S)-3-(1-carbamimidoyl- piperidin-3-yl)-propanoic acid at P1.
Warner-Lambert
24
The design of potent and selective inhibitors of thrombin utilizing a piperazinedione template: part 2.
Warner-Lambert
17
The design of potent and selective inhibitors of thrombin utilizing a piperazinedione template: part 1.
Warner-Lambert
11
Synthesis and structure-activity relationship of potent bicyclic lactam thrombin inhibitors.
Biochem Therapeutic
14
Potent and selective bicyclic lactam inhibitors of thrombin: Part 3: P1' modifications.
Warner-Lambert
7
Potent and selective bicyclic lactam inhibitors of thrombin: Part 2: P1 modifications.
Warner-Lambert
24
Potent bicyclic lactam inhibitors of thrombin: Part I: P3 modifications.
Biochem Therapeutic
46
Design and synthesis of potent Gram-negative specific LpxC inhibitors.
Merck Research Laboratories
64
C3-carbon linked glutarimide degronimers for target protein degradation
C4 Therapeutics